While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

KARACHI: In a patriarchal society, where women’s reproductive health is a hushed affair, the secondary socialisation of young ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized ...

We preselected all newsletters you had before unsubscribing.

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, Gardasil.